Evofem Biosciences (Evofem Biosciences) Days Payable : 1,588.70 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences Days Payable?

Evofem Biosciences's average Accounts Payable for the three months ended in Dec. 2023 was $16.61 Mil. Evofem Biosciences's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.95 Mil. Hence, Evofem Biosciences's Days Payable for the three months ended in Dec. 2023 was 1,588.70.

The historical rank and industry rank for Evofem Biosciences's Days Payable or its related term are showing as below:

EVFM' s Days Payable Range Over the Past 10 Years
Min: 896.92 Med: 994.5 Max: 6492.4
Current: 943.34

During the past 12 years, Evofem Biosciences's highest Days Payable was 6492.40. The lowest was 896.92. And the median was 994.50.

EVFM's Days Payable is ranked better than
83.89% of 714 companies
in the Biotechnology industry
Industry Median: 147.95 vs EVFM: 943.34

Evofem Biosciences's Days Payable declined from Dec. 2022 (3,508.25) to Dec. 2023 (1,588.70). It may suggest that Evofem Biosciences accelerated paying its suppliers.

Evofem Biosciences Days Payable Historical Data

The historical data trend for Evofem Biosciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences Days Payable Chart

Evofem Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

6,492.40

943.19

1,045.81

896.92

Evofem Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															3,508.25	1,120.10	715.28	805.50	1,588.70

Competitive Comparison of Evofem Biosciences's Days Payable

For the Biotechnology subindustry, Evofem Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evofem Biosciences's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Days Payable falls into.

Evofem Biosciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Evofem Biosciences's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (14.984	+	17.02)	/	2 )	/	6.512	*	365
=	16.002					/	6.512	*	365
=	896.92

Evofem Biosciences's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (16.199	+	17.02)	/	2 )	/	0.954	*	365 / 4
=	16.6095					/	0.954	*	365 / 4
=	1,588.70

Evofem Biosciences Days Payable Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Evofem Biosciences (Evofem Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122

Website

https://www.evofem.com

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.

Executives

Yan Zhang	officer: Chief Financial Officer	6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar	director, 10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip	director	12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca	officer: Chief Commercial Officer	12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier	director, officer: Chief Executive Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick	officer: General Counsel and Secretary	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File	officer: Chief Financial Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans	officer: Chief Commercial Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd.	10 percent owner	1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd	10 percent owner	65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp	10 percent owner	767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell	officer: Chief Medical Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130